Listen to SAHPRA's Pharmacovigilance Manager, Mafora Matlala as she speaks on CapeTalk radio regarding recalls and withdrawal of all pholcodine-containing medicines. This decision was taken in April 2022.

CapeTalk Interview on withdrawal of all pholcodine-containing medicines

ChaiFm interview of Mafora Matlala Manager of Pharmacovigilance

Mafora Matlala, SAHPRA's Pharmacovigilance Manager, discusses  Risks Of Pholcodine-Containing Medicines with Michael McKenna from ChaiFM.

ChaiFM - Interview on Risks Of Pholcodine-Containing Medicines

Mafora Matlala, SAHPRA's Pharmacovigilance Manager, discusses the withdrawal of pholcodine-containing medicines on SAFM's Midday Live.

SAFM Interview - Withdrawal of Pholcodine-Containing Medicines

Deon Poovan, Senior Manager: Inspectorate and Regulatory Compliance, speaks about SAHPRA's recall of Lubri-A, sterile lubricating gel.

PowerFM interview with Deon Poovan on recall of Lubri-A

SAHPRA's Deon Poovan, Senior Manager for Inspectorate and Regulatory Compliance, urges public to use registered Ozempic products. SAHPRA has not authorised/registered Ozempic for weight-loss, therefore, use in that regard would be off-label. It must be noted that only a healthcare practitioner can make a Schedule 4 product available off-label as they would provide the requisite guidance and support to the patient/individual.

Radio 786 interview with Deon Poovan urging public to use registered Ozempic products

SAHPRA's Daphney Fafudi, Manager for Regulatory Compliance, urges the public to use registered Ozempic products. SAHPRA has not authorised/registered Ozempic for weight-loss, therefore, use in that regard would be off-label. It must be noted that only a healthcare practitioner can make a Schedule 4 product available off-label as they would provide the requisite guidance and support to the patient/individual.

SAFM interview with Daphney Fafudi urging public to use registered Ozempic products

SAHPRA has recalled two batches of Benylin Paediatric Syrup after receiving a report from the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) regarding the detection of high levels of diethylene glycol.

SAHPRA recalls two batches of Benylin Paediatric Syrup

The South African Health Products Regulatory Authority (SAHPRA) and the Botswana Medicines Regulatory Authority (BoMRA) have signed a memorandum of understanding (MoU) that will see the two regulators partner on various areas to improve access to new medicines and therapies, the control of falsified and substandard medicines, and the sharing of best practice and regulatory information, amongst others.

SAHPRA Partners With BoMRA

On 13 April 2024, the South African Health Products Regulatory Authority (SAHPRA) initiated a precautionary recall of two batches of Benylin Paediatric Syrup (batch numbers 329303 and 329304), in response to reported high levels of diethylene glycol in an alert by the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC). The recall was implemented as a precaution to protect lives while SAHPRA investigated the reported high levels of diethylene glycol.

As the national regulatory authority for health products in South Africa, SAHPRA implements health product recalls as a crucial measure to address safety concerns or quality issues in the interest of public health.

SAHPRA Partners With BoMRA

SAHPRA

Related tracks